Notebook

The World Health Organization (WHO), based in Geneva, will back large-scale clinical trials of two experimental HIV vaccines that failed earlier this year to win similar approval in the United States. In June, Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), chose not to support the complex and costly trials because "the science wasn't there to justify it." Each vaccine relies on stimul


Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The World Health Organization (WHO), based in Geneva, will back large-scale clinical trials of two experimental HIV vaccines that failed earlier this year to win similar approval in the United States. In June, Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), chose not to support the complex and costly trials because "the science wasn't there to justify it." Each vaccine relies on stimulating an immune response to the surface protein gp120 on the virus thought to cause AIDS. Apparently, the international health organization looked at the same data Fauci did, from smaller trials in humans, and saw sufficient immune system improvement demonstrated to warrant further studies. "The World Health Organization, in contrast to the NIAID, has decided to go ahead and test these vaccines in efficacy trials and put their blessing on that," says Don Francis, the clinical scientist managing the trials for Genentech. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide